IL212102A - Use of Th1 Allogeneic Memory Cell Preparations in Th1 Immune Response Injection - Google Patents
Use of Th1 Allogeneic Memory Cell Preparations in Th1 Immune Response InjectionInfo
- Publication number
- IL212102A IL212102A IL212102A IL21210211A IL212102A IL 212102 A IL212102 A IL 212102A IL 212102 A IL212102 A IL 212102A IL 21210211 A IL21210211 A IL 21210211A IL 212102 A IL212102 A IL 212102A
- Authority
- IL
- Israel
- Prior art keywords
- allogeneic
- priming
- compositions
- subject
- memory cells
- Prior art date
Links
- 230000029662 T-helper 1 type immune response Effects 0.000 title 1
- 230000000735 allogeneic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000037452 priming Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10169208P | 2008-10-01 | 2008-10-01 | |
| US12/570,442 US9695397B2 (en) | 2008-10-01 | 2009-09-30 | Th1 vaccination priming for active immunotherapy |
| PCT/US2009/059177 WO2010039924A2 (en) | 2008-10-01 | 2009-10-01 | Th1 vaccination priming for active immunotheraphy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL212102A0 IL212102A0 (en) | 2011-06-30 |
| IL212102A true IL212102A (en) | 2016-06-30 |
Family
ID=42074205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL212102A IL212102A (en) | 2008-10-01 | 2011-04-03 | Use of Th1 Allogeneic Memory Cell Preparations in Th1 Immune Response Injection |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9695397B2 (https=) |
| EP (1) | EP2334309B1 (https=) |
| JP (4) | JP6042065B2 (https=) |
| CN (2) | CN104758926B (https=) |
| CA (1) | CA2739255C (https=) |
| DK (1) | DK2334309T3 (https=) |
| ES (1) | ES2635516T3 (https=) |
| HU (1) | HUE034855T2 (https=) |
| IL (1) | IL212102A (https=) |
| PL (1) | PL2334309T3 (https=) |
| PT (1) | PT2334309T (https=) |
| WO (1) | WO2010039924A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012502233A1 (en) * | 2010-04-13 | 2022-10-05 | Immunovative Therapies Ltd | Methods and compositions for inhibition of treg cells |
| SG10201908048QA (en) | 2014-01-08 | 2019-10-30 | Immunovative Therapies Ltd | Treatment of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome |
| TWI714529B (zh) * | 2015-05-20 | 2021-01-01 | 以色列商梵提夫免疫療法公司 | 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療 |
| US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
| TWI905535B (zh) | 2018-04-23 | 2025-11-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
| US20250319132A1 (en) * | 2024-04-16 | 2025-10-16 | Mirror Biologics, Inc. | Methods and compositions for improving the immune response against viral pathogens |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6051237A (en) * | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| US20080199495A1 (en) * | 1999-04-15 | 2008-08-21 | Monash University | Stimulation of thymus for vaccination development |
| US20020131960A1 (en) * | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
| AU2001294834A1 (en) * | 2000-09-26 | 2002-04-08 | Beth Israel Deaconess Medical Center | Recombinant bcg vaccines for the prevention and treatment of cancer |
| US20070025958A1 (en) * | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| JP2004536800A (ja) * | 2001-05-09 | 2004-12-09 | アルカベロ アクチェセルスカプ | Ｔｈ１／ｔｈ２比を変調することによりｔｈ１及びｔｈ２細胞関連疾患を予防又は治療するための医薬組成物 |
| US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| US20040013649A1 (en) * | 2002-05-10 | 2004-01-22 | Inex Pharmaceuticals Corporation | Cancer vaccines and methods of using the same |
| US20040115224A1 (en) * | 2002-12-16 | 2004-06-17 | Tsuneya Ohno | Preparation and administration of hybrid cell vaccines for the prevention of cancer |
| NZ542134A (en) * | 2003-03-04 | 2009-06-26 | Alexion Pharma Inc | Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells |
| US7402431B2 (en) * | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| CA2555714C (en) * | 2004-02-26 | 2013-12-03 | Immunovative Therapies, Ltd. | Methods for preparing t-cells for cell therapy |
| US7181931B2 (en) * | 2005-02-28 | 2007-02-27 | White Dennis M | Method and apparatus for fitting chain jewelry assembly on an individual |
| US7435692B2 (en) * | 2005-10-19 | 2008-10-14 | Tokyo Electron Limited | Gas jet reduction of iso-dense field thickness bias for gapfill process |
-
2009
- 2009-09-30 US US12/570,442 patent/US9695397B2/en active Active
- 2009-10-01 WO PCT/US2009/059177 patent/WO2010039924A2/en not_active Ceased
- 2009-10-01 DK DK09818495.5T patent/DK2334309T3/en active
- 2009-10-01 CN CN201510137976.8A patent/CN104758926B/zh active Active
- 2009-10-01 JP JP2011530213A patent/JP6042065B2/ja active Active
- 2009-10-01 HU HUE09818495A patent/HUE034855T2/en unknown
- 2009-10-01 PL PL09818495T patent/PL2334309T3/pl unknown
- 2009-10-01 PT PT98184955T patent/PT2334309T/pt unknown
- 2009-10-01 ES ES09818495.5T patent/ES2635516T3/es active Active
- 2009-10-01 EP EP09818495.5A patent/EP2334309B1/en active Active
- 2009-10-01 CA CA2739255A patent/CA2739255C/en active Active
- 2009-10-01 CN CN200980147749.6A patent/CN102227224B/zh active Active
-
2011
- 2011-04-03 IL IL212102A patent/IL212102A/en active IP Right Grant
-
2014
- 2014-04-28 JP JP2014092886A patent/JP2014139247A/ja not_active Withdrawn
-
2016
- 2016-03-01 JP JP2016038729A patent/JP2016104818A/ja not_active Withdrawn
-
2017
- 2017-06-22 US US15/630,592 patent/US10744158B2/en active Active
- 2017-06-22 US US15/630,581 patent/US20170290857A1/en not_active Abandoned
- 2017-11-02 JP JP2017212788A patent/JP6789913B2/ja active Active
-
2020
- 2020-07-14 US US16/928,884 patent/US11833173B2/en active Active
-
2023
- 2023-10-26 US US18/495,532 patent/US20240050480A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN102227224A (zh) | 2011-10-26 |
| CN104758926B (zh) | 2017-09-22 |
| IL212102A0 (en) | 2011-06-30 |
| US20170290857A1 (en) | 2017-10-12 |
| CN102227224B (zh) | 2015-03-25 |
| US20170281743A1 (en) | 2017-10-05 |
| JP2012504638A (ja) | 2012-02-23 |
| PT2334309T (pt) | 2017-10-06 |
| DK2334309T3 (en) | 2017-07-17 |
| CA2739255A1 (en) | 2010-04-08 |
| US20100086561A1 (en) | 2010-04-08 |
| HK1211230A1 (en) | 2016-05-20 |
| JP2018016651A (ja) | 2018-02-01 |
| US20240050480A1 (en) | 2024-02-15 |
| US11833173B2 (en) | 2023-12-05 |
| CA2739255C (en) | 2019-04-02 |
| ES2635516T3 (es) | 2017-10-04 |
| HUE034855T2 (en) | 2018-03-28 |
| EP2334309B1 (en) | 2017-05-31 |
| EP2334309A4 (en) | 2013-01-09 |
| CN104758926A (zh) | 2015-07-08 |
| PL2334309T3 (pl) | 2017-11-30 |
| EP2334309A2 (en) | 2011-06-22 |
| US9695397B2 (en) | 2017-07-04 |
| US20200338127A1 (en) | 2020-10-29 |
| US10744158B2 (en) | 2020-08-18 |
| JP6042065B2 (ja) | 2016-12-14 |
| JP6789913B2 (ja) | 2020-11-25 |
| JP2016104818A (ja) | 2016-06-09 |
| WO2010039924A3 (en) | 2010-07-22 |
| JP2014139247A (ja) | 2014-07-31 |
| WO2010039924A2 (en) | 2010-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2403472A4 (en) | AMPHOLYTIC TERPOLYMERS FOR USE IN PERSONAL CARE COMPOSITIONS | |
| SI2569008T1 (sl) | Himere OSPA in njihova uporaba v cepivih | |
| EP2646468A4 (en) | ANTI-NGF COMPOSITIONS AND THEIR USE | |
| PL2616064T3 (pl) | Gotowe do zastosowania formulacje ketorolaku | |
| EP2621504A4 (en) | COMPOSITION FOR PERSONAL HYGIENE CARE CONTAINING YEAST EXTRACT AND HEXAPEPTIDE | |
| ZA201106429B (en) | Improvements in and relating to posts | |
| IL212102A (en) | Use of Th1 Allogeneic Memory Cell Preparations in Th1 Immune Response Injection | |
| PL2651425T3 (pl) | Kompozycja na bazie wyciągu z alg i co najmniej jednego zeolitu nasyconego srebrem do stosowania do jamy ustnej i do zębów | |
| IL222343A0 (en) | Compositions comprising allogeneic th1 cells and uses thereof | |
| GB201012903D0 (en) | Improvements in and relating to pharmaceutical compositions | |
| GB2469754B (en) | Composition for use in the sublingual delivery of medicaments to humans | |
| GB201004936D0 (en) | Improvements in and relating to furniture | |
| EP2515930A4 (en) | METHODS AND COMPOSITIONS BASED ON REDUCED MET PHOSPHORYLATION BY CHEMOTAXIN 2 DERIVED FROM LEUKOCYTE CELLS IN TUMOR CELLS | |
| GB201009275D0 (en) | Improvements in or relating to compositions | |
| EP2363132A4 (en) | USE OF SOPHORICOSIDE IN DRUG MANUFACTURE | |
| ZA201301208B (en) | Formulations for bovine granulocyte colony stimulating factor and variants thereof | |
| GB201006592D0 (en) | Improvements in and relating to nutritional compositions | |
| ZA201200946B (en) | Cosmetic compositions with gold particles and alkyl acid monoethanolamides | |
| ZA201209745B (en) | Compositions containing flavones and anthelmintics | |
| TWM373679U (en) | Shining structure of cosmetic container | |
| GB201015172D0 (en) | Improvements in or relating to storage | |
| GB201015173D0 (en) | Improvements in or relating to storage | |
| GB201005993D0 (en) | Improvements in or relating to storage | |
| GB201005997D0 (en) | Improvements in or relating to storage | |
| GB201015171D0 (en) | Improvements in or relating to storage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |